Consequently, the shift to N-cadherin in the validation study is linked to heightened malignant invasiveness, high histological grade, and lymph node metastasis, as it was mainly expressed in advanced-stage patients. Here, CDH2 is linked to metastatic malignant neoplasm in the lymph nodes.